News

Capricor falls after long-term trial data for Duchenne therapy
Capricor Therapeutics (NASDAQ:CAPR) lost ~15% on Friday after the cell therapy developer posted long-term data from an ...
Stocktwits on MSN1h
Capricor Stock Slumps 16% On Report Of Key FDA Executive’s Removal, But Retail’s Hopeful About New 4-Year Deramiocel Data
Shares of Capricor Therapeutics (CAPR) tumbled 16% on Friday morning following reports that Nicole Verdun, director of the ...
Investing.com India2h
Capricor Therapeutics stock plunges after key FDA officials placed on leave
Investing.com -- Capricor Therapeutics Inc (NASDAQ: CAPR) stock tumbled 20.4% following news that two top FDA officials overseeing cell and gene therapies have been placed on administrative leave.
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
Four-year data show preservation of cardiac function, including LVEFSkeletal muscle disease progression continues to slow ...
Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
Cheetah Mobile posted a quarterly loss of 11 cents per share, versus a year-ago loss of 32 cents per share. The company's ...